Q1 EPS Estimate for Voyager Therapeutics Reduced by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Wedbush cut their Q1 2025 earnings per share estimates for Voyager Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.37) per share for the quarter, down from their prior estimate of ($0.27). Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics' Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at ($0.87) EPS.

Several other equities research analysts have also recently commented on VYGR. StockNews.com cut Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Canaccord Genuity Group dropped their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a "buy" rating and a $12.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $14.86.

Remove Ads

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock traded down $0.26 during trading on Monday, hitting $3.84. 160,405 shares of the company's stock traded hands, compared to its average volume of 472,289. Voyager Therapeutics has a 1 year low of $3.56 and a 1 year high of $10.66. The stock has a market capitalization of $211.72 million, a P/E ratio of 5.42 and a beta of 0.99. The business has a 50-day simple moving average of $4.72 and a 200-day simple moving average of $5.77.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million during the quarter, compared to analysts' expectations of $16.58 million. During the same period in the prior year, the company posted $1.25 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VYGR. Empowered Funds LLC raised its stake in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after buying an additional 2,278 shares during the period. Intech Investment Management LLC bought a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $74,000. Massachusetts Financial Services Co. MA raised its stake in Voyager Therapeutics by 19.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company's stock valued at $1,005,000 after purchasing an additional 28,333 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company's stock valued at $804,000 after purchasing an additional 3,473 shares during the period. Finally, FMR LLC raised its stake in Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company's stock valued at $541,000 after purchasing an additional 19,622 shares during the period. Institutional investors own 48.03% of the company's stock.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company's stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 10,778 shares of company stock valued at $58,548 over the last quarter. 4.53% of the stock is currently owned by company insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.